General Information of Target

Target ID LDTP00157
Target Name Unconventional myosin-Ig (MYO1G)
Gene Name MYO1G
Gene ID 64005
Synonyms
HA2; Unconventional myosin-Ig [Cleaved into: Minor histocompatibility antigen HA-2; mHag HA-2)]
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MEDEEGPEYGKPDFVLLDQVTMEDFMRNLQLRFEKGRIYTYIGEVLVSVNPYQELPLYGP
EAIARYQGRELYERPPHLYAVANAAYKAMKHRSRDTCIVISGESGAGKTEASKHIMQYIA
AVTNPSQRAEVERVKDVLLKSTCVLEAFGNARTNRNHNSSRFGKYMDINFDFKGDPIGGH
IHSYLLEKSRVLKQHVGERNFHAFYQLLRGSEDKQLHELHLERNPAVYNFTHQGAGLNMT
VHSALDSDEQSHQAVTEAMRVIGFSPEEVESVHRILAAILHLGNIEFVETEEGGLQKEGL
AVAEEALVDHVAELTATPRDLVLRSLLARTVASGGRELIEKGHTAAEASYARDACAKAVY
QRLFEWVVNRINSVMEPRGRDPRRDGKDTVIGVLDIYGFEVFPVNSFEQFCINYCNEKLQ
QLFIQLILKQEQEEYEREGITWQSVEYFNNATIVDLVERPHRGILAVLDEACSSAGTITD
RIFLQTLDMHHRHHLHYTSRQLCPTDKTMEFGRDFRIKHYAGDVTYSVEGFIDKNRDFLF
QDFKRLLYNSTDPTLRAMWPDGQQDITEVTKRPLTAGTLFKNSMVALVENLASKEPFYVR
CIKPNEDKVAGKLDENHCRHQVAYLGLLENVRVRRAGFASRQPYSRFLLRYKMTCEYTWP
NHLLGSDKAAVSALLEQHGLQGDVAFGHSKLFIRSPRTLVTLEQSRARLIPIIVLLLQKA
WRGTLARWRCRRLRAIYTIMRWFRRHKVRAHLAELQRRFQAARQPPLYGRDLVWPLPPAV
LQPFQDTCHALFCRWRARQLVKNIPPSDMPQIKAKVAAMGALQGLRQDWGCRRAWARDYL
SSATDNPTASSLFAQRLKTLQDKDGFGAVLFSSHVRKVNRFHKIRNRALLLTDQHLYKLD
PDRQYRVMRAVPLEAVTGLSVTSGGDQLVVLHARGQDDLVVCLHRSRPPLDNRVGELVGV
LAAHCQGEGRTLEVRVSDCIPLSHRGVRRLISVEPRPEQPEPDFRCARGSFTLLWPSR
Target Bioclass
Enzyme
Family
TRAFAC class myosin-kinesin ATPase superfamily, Myosin family
Subcellular location
Cell membrane
Function
Unconventional myosin required during immune response for detection of rare antigen-presenting cells by regulating T-cell migration. Unconventional myosins are actin-based motor molecules with ATPase activity and serve in intracellular movements. Acts as a regulator of T-cell migration by generating membrane tension, enforcing cell-intrinsic meandering search, thereby enhancing detection of rare antigens during lymph-node surveillance, enabling pathogen eradication. Also required in B-cells, where it regulates different membrane/cytoskeleton-dependent processes. Involved in Fc-gamma receptor (Fc-gamma-R) phagocytosis.; [Minor histocompatibility antigen HA-2]: Constitutes the minor histocompatibility antigen HA-2. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and their expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. HA-2 is restricted to MHC class I HLA-A*0201.
Uniprot ID
B0I1T2
Ensemble ID
ENST00000258787.12
HGNC ID
HGNC:13880

Target Site Mutations in Different Cell Lines

Cell line Mutation details Probe for labeling this protein in this cell
HCT15 SNV: p.E54K; p.T844N .
IM95 SNV: p.A278T .
KMCH1 SNV: p.Y548C .
LS123 SNV: p.R545W .
MFE319 SNV: p.L699P .
MOLT4 Deletion: p.G68AfsTer22
SNV: p.G294E
IA-alkyne    Probe Info 
NCIH2286 SNV: p.R462H .
NCIH446 SNV: p.R324P .
PEO1 SNV: p.Y350F .
RL952 SNV: p.E73V .
SCC25 SNV: p.C793W .
SKMEL2 SNV: p.R745K .
SNGM SNV: p.L1014F .
SW837 SNV: p.S159P; p.R906W .
UMUC3 SNV: p.G611R .

Probe(s) Labeling This Target

ABPP Probe
Click To Hide/Show 10 Probe Related to This Target
Probe name Structure Binding Site(Ratio) Interaction ID Ref
TH211
 Probe Info 
Y350(20.00); Y548(16.05); Y205(15.23); Y624(9.86)  LDD0260  [1]
DBIA
 Probe Info 
C618(357.39); C503(9.21)  LDD0209  [2]
4-Iodoacetamidophenylacetylene
 Probe Info 
C601(0.00); C788(0.00); C793(0.00); C97(0.00)  LDD0038  [3]
IA-alkyne
 Probe Info 
C788(0.00); C793(0.00); C97(0.00); C472(0.00)  LDD0036  [3]
IPIAA_H
 Probe Info 
N.A.  LDD0030  [4]
IPIAA_L
 Probe Info 
C942(0.00); C655(0.00)  LDD0031  [4]
Lodoacetamide azide
 Probe Info 
C788(0.00); C793(0.00); C97(0.00); C472(0.00)  LDD0037  [3]
Compound 10
 Probe Info 
C143(0.00); C965(0.00)  LDD2216  [5]
Compound 11
 Probe Info 
C143(0.00); C965(0.00)  LDD2213  [5]
YN-1
 Probe Info 
N.A.  LDD0447  [6]

Competitor(s) Related to This Target

Competitor ID Name Cell line Binding Site(Ratio) Interaction ID Ref
 LDCM0625  F8 Ramos C979(1.09); C143(0.78); C601(2.10); C965(0.64)  LDD2187  [7]
 LDCM0572  Fragment10 Ramos C979(1.51); C143(0.81); C601(0.96); C965(0.63)  LDD2189  [7]
 LDCM0573  Fragment11 Ramos C979(0.21); C143(0.23); C655(2.77); C965(6.91)  LDD2190  [7]
 LDCM0574  Fragment12 Ramos C979(1.44); C143(1.10); C601(1.30); C965(1.60)  LDD2191  [7]
 LDCM0575  Fragment13 Ramos C979(0.94); C143(0.85); C965(0.84)  LDD2192  [7]
 LDCM0576  Fragment14 Ramos C979(1.03); C143(1.32); C601(0.69); C965(1.07)  LDD2193  [7]
 LDCM0579  Fragment20 Ramos C979(1.76); C143(0.90); C601(1.29)  LDD2194  [7]
 LDCM0580  Fragment21 Ramos C979(1.07); C143(0.97); C601(1.73); C655(1.13)  LDD2195  [7]
 LDCM0582  Fragment23 Ramos C979(0.71); C143(0.67); C601(1.20); C655(0.70)  LDD2196  [7]
 LDCM0578  Fragment27 Ramos C979(1.08); C143(0.77); C601(0.79); C655(1.08)  LDD2197  [7]
 LDCM0586  Fragment28 Ramos C979(0.45); C143(0.47); C601(0.83); C965(0.82)  LDD2198  [7]
 LDCM0588  Fragment30 Ramos C979(1.24); C143(0.83); C601(1.94); C965(0.67)  LDD2199  [7]
 LDCM0589  Fragment31 Ramos C979(0.83); C143(0.74); C601(1.89); C655(0.78)  LDD2200  [7]
 LDCM0590  Fragment32 Ramos C979(1.41); C143(0.74); C601(1.48); C965(0.96)  LDD2201  [7]
 LDCM0468  Fragment33 Ramos C979(0.96); C143(0.86); C601(1.78); C965(0.59)  LDD2202  [7]
 LDCM0596  Fragment38 Ramos C979(0.98); C143(0.61); C601(3.59); C655(1.19)  LDD2203  [7]
 LDCM0566  Fragment4 Ramos C979(0.97); C143(3.75); C601(1.09); C965(1.17)  LDD2184  [7]
 LDCM0610  Fragment52 Ramos C979(1.73); C143(0.80); C965(0.50)  LDD2204  [7]
 LDCM0614  Fragment56 Ramos C979(1.48); C143(0.71); C601(1.49); C965(0.56)  LDD2205  [7]
 LDCM0569  Fragment7 Ramos C979(1.34); C143(1.44); C601(0.75); C965(0.89)  LDD2186  [7]
 LDCM0571  Fragment9 Ramos C979(1.84); C143(1.78); C601(0.99); C965(1.13)  LDD2188  [7]
 LDCM0022  KB02 T cell C831(9.92)  LDD1703  [8]
 LDCM0023  KB03 Jurkat C618(357.39); C503(9.21)  LDD0209  [2]
 LDCM0024  KB05 HMCB C472(2.57); C942(1.46); C503(1.99); C965(3.81)  LDD3312  [9]

References

1 Chemoproteomic profiling of kinases in live cells using electrophilic sulfonyl triazole probes. Chem Sci. 2021 Jan 21;12(9):3295-3307. doi: 10.1039/d0sc06623k.
2 Covalent Inhibition by a Natural Product-Inspired Latent Electrophile. J Am Chem Soc. 2023 May 24;145(20):11097-11109. doi: 10.1021/jacs.3c00598. Epub 2023 May 15.
3 Enhancing Cysteine Chemoproteomic Coverage through Systematic Assessment of Click Chemistry Product Fragmentation. Anal Chem. 2022 Mar 8;94(9):3800-3810. doi: 10.1021/acs.analchem.1c04402. Epub 2022 Feb 23.
Mass spectrometry data entry: PXD028853
4 SP3-Enabled Rapid and High Coverage Chemoproteomic Identification of Cell-State-Dependent Redox-Sensitive Cysteines. Mol Cell Proteomics. 2022 Apr;21(4):100218. doi: 10.1016/j.mcpro.2022.100218. Epub 2022 Feb 25.
Mass spectrometry data entry: PXD029500 , PXD031647
5 Multiplexed CuAAC Suzuki-Miyaura Labeling for Tandem Activity-Based Chemoproteomic Profiling. Anal Chem. 2021 Feb 2;93(4):2610-2618. doi: 10.1021/acs.analchem.0c04726. Epub 2021 Jan 20.
Mass spectrometry data entry: PXD022279
6 Ynamide Electrophile for the Profiling of Ligandable Carboxyl Residues in Live Cells and the Development of New Covalent Inhibitors. J Med Chem. 2022 Aug 11;65(15):10408-10418. doi: 10.1021/acs.jmedchem.2c00272. Epub 2022 Jul 26.
7 Site-specific quantitative cysteine profiling with data-independent acquisition-based mass spectrometry. Methods Enzymol. 2023;679:295-322. doi: 10.1016/bs.mie.2022.07.037. Epub 2022 Sep 7.
Mass spectrometry data entry: PXD027578
8 An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. Cell. 2020 Aug 20;182(4):1009-1026.e29. doi: 10.1016/j.cell.2020.07.001. Epub 2020 Jul 29.
9 DrugMap: A quantitative pan-cancer analysis of cysteine ligandability. Cell. 2024 May 9;187(10):2536-2556.e30. doi: 10.1016/j.cell.2024.03.027. Epub 2024 Apr 22.
Mass spectrometry data entry: PXD047840